Daily Endocrinology Research Analysis
Three high-impact endocrinology studies stood out today: a Nature Communications paper mechanistically links DENND1A regulatory activity to elevated testosterone in PCOS, a JCI study uncovers SEC61B-driven ER calcium leak as a cause of platelet hyperreactivity in diabetes, and a JCEM cohort/function study identifies a recurrent deep intronic CYP11B1 splice variant refining diagnosis of 11β-hydroxylase deficiency. Together they advance mechanistic understanding and genomic diagnostics with potent
Summary
Three high-impact endocrinology studies stood out today: a Nature Communications paper mechanistically links DENND1A regulatory activity to elevated testosterone in PCOS, a JCI study uncovers SEC61B-driven ER calcium leak as a cause of platelet hyperreactivity in diabetes, and a JCEM cohort/function study identifies a recurrent deep intronic CYP11B1 splice variant refining diagnosis of 11β-hydroxylase deficiency. Together they advance mechanistic understanding and genomic diagnostics with potential therapeutic implications.
Research Themes
- Gene regulatory mechanisms driving endocrine phenotypes (PCOS hyperandrogenism)
- ER stress and calcium handling in diabetic platelet hyperreactivity
- Genomic diagnostics and deep intronic variants in congenital adrenal hyperplasia
Selected Articles
1. Gene regulatory activity associated with polycystic ovary syndrome revealed DENND1A-dependent testosterone production.
Using high-throughput reporter assays, CRISPR-based epigenome editing, and genetic association, the authors fine-mapped regulatory elements at PCOS loci (GATA4, FSHB, DENND1A). Perturbation that increased endogenous DENND1A expression elevated testosterone in an adrenal cell model, linking disease-associated regulatory variation to a core PCOS endophenotype.
Impact: This is among the first functional demonstrations connecting fine-mapped regulatory variants at DENND1A to androgen excess, providing a mechanistic bridge from GWAS signals to PCOS biology.
Clinical Implications: Improved identification of causal regulatory elements may enable genetic risk stratification and inform development of targeted therapies modulating DENND1A pathways in PCOS.
Key Findings
- High-throughput reporter assays and CRISPR epigenome editing identified functional regulatory elements at GATA4, FSHB, and DENND1A PCOS loci.
- Increasing endogenous DENND1A expression in an adrenal cell model elevated testosterone, linking regulatory perturbation to hyperandrogenism.
- Genetic association and fine mapping supported causal noncoding variants driving PCOS risk through gene regulation.
Methodological Strengths
- Integration of functional genomics (massively parallel reporter assays, CRISPR-based epigenome editing) with human genetic association
- Direct functional readout (testosterone production) following targeted regulatory perturbation
Limitations
- Primary functional validation performed in an adrenal cell model rather than human ovarian/thecal tissue
- Translational impact not yet tested in vivo or in clinical cohorts
Future Directions: Validate regulatory variants in disease-relevant ovarian cell types and in vivo models; explore pharmacologic modulation of DENND1A regulatory pathways to reduce androgen excess.
Polycystic ovary syndrome (PCOS) is among the most common disorders affecting up to 15% of the menstruating population globally. It is the leading cause of anovulatory infertility and a major risk factor for type 2 diabetes. Elevated testosterone levels are a core endophenotype. Despite that prevalence, the underlying causes remain unknown. PCOS genome-wide association studies (GWAS) have reproducibly mapped a number of susceptibility loci, including one encompassing a gene regulating androgen biosynthesis, DENND1A. Id
2. SEC61B regulates calcium flux and platelet hyperreactivity in diabetes.
Proteomics revealed increased platelet SEC61B in human and murine hyperglycemia. SEC61B overexpression increased cytosolic Ca2+ and reduced protein synthesis, consistent with ER stress in diabetic platelets. Pharmacologic SEC61 inhibition reduced Ca2+ flux and platelet aggregation in vitro and in vivo, implicating an ER leak-channel mechanism for diabetic platelet hyperreactivity.
Impact: Uncovers a targetable ER calcium leak mechanism via SEC61B that links ER stress to platelet hyperreactivity in diabetes, offering a mechanistic basis for antithrombotic strategies.
Clinical Implications: SEC61 pathway modulation could represent a novel antiplatelet approach in diabetes; monitoring ER stress markers may identify patients at risk of hyperreactivity and antiplatelet nonresponse.
Key Findings
- Platelet SEC61B expression is increased in humans and mice with hyperglycemia and in megakaryocytes from hyperglycemic mice.
- SEC61B overexpression increases cytosolic calcium and decreases protein synthesis; diabetic platelets display ER stress signatures.
- Pharmacologic SEC61 inhibition (anisomycin) reduces platelet calcium flux and aggregation in vitro and in vivo.
Methodological Strengths
- Unbiased high-sensitivity proteomics across human and murine samples with orthogonal cellular validation
- In vitro and in vivo functional testing of pathway inhibition linking mechanism to phenotype
Limitations
- Pharmacologic inhibitor (anisomycin) is not SEC61B-selective and broadly affects protein synthesis
- Clinical validation in diabetic patients (thrombosis outcomes) is not provided
Future Directions: Develop selective SEC61 modulators and test antithrombotic efficacy in diabetic models and clinical trials; evaluate ER stress biomarkers as predictors of platelet hyperreactivity.
Platelet hyperreactivity increases the risk of cardiovascular thrombosis in diabetes and failure of antiplatelet drug therapies. Elevated basal and agonist-induced calcium flux is a fundamental cause of platelet hyperreactivity in diabetes; however, the mechanisms responsible for this remain largely unknown. Using a high-sensitivity, unbiased proteomic platform, we consistently detected over 2,400 intracellular proteins and identified proteins that were differentially released by platelets in type 2 diabetes. We identified
3. A recurrent splice variant sheds light on 11beta-hydroxylase deficiency in a unique large cohort.
Among 250 patients with 11βOHD, a recurrent deep intronic CYP11B1 variant (c.954+148C>G) was identified in 44 cases. Minigene assays demonstrated aberrant splicing via a cryptic donor site. Carriers showed lower steroid precursor levels and delayed pubertal onset compared with carriers of severe variants, underscoring diagnostic value of deep intronic screening.
Impact: Defines a recurrent deep intronic splice variant with functional validation and genotype–phenotype correlation, refining molecular diagnosis of 11βOHD and preventing missed diagnoses.
Clinical Implications: In suspected 11βOHD, sequencing strategies should include deep intronic regions and functional splicing assays to avoid false-negative results and guide tailored management.
Key Findings
- A recurrent deep intronic CYP11B1 variant (c.954+148C>G) was present in 44 of 250 11βOHD patients.
- Minigene reporter assays confirmed aberrant splicing due to activation of a cryptic donor site.
- Variant carriers had lower steroid precursor levels and delayed pubertal onset versus carriers of severe variants.
Methodological Strengths
- Large cohort genotyping spanning three decades with functional minigene validation
- Genotype–phenotype correlation improving clinical interpretability
Limitations
- Retrospective design and single-laboratory recruitment may introduce selection bias
- Functional assays used minigene systems rather than patient-derived tissues
Future Directions: Expand deep intronic screening across diverse populations; develop clinical assays for splicing defects; evaluate impact of variant-aware diagnosis on treatment outcomes.
CONTEXT: Congenital adrenal hyperplasia (CAH) can be due to 11β-hydroxylase deficiency (11βOHD). Sporadic reports of 11βOHD are frequent but overviews on molecular landscape in some populations are lacking. OBJECTIVE: The aim of this research was to compile a genetic landscape from a 11βOHD cohort, and to report a novel yet recurrent splice variant. DESIGN: An overview of CYP11B1 variants in a cohort of 11βOHD is presented here. The functional impact of NM_000497.4(CYP11B1):c.954+148C>G was studied in silico and in vitro, and a genotype-phenotype correlation study ("SPLICYP" study, #22_1787) was conducted. SETTING: Patients with 11βOHD who underwent genetic testing at the Biochemistry and Molecular Biology department were considered for inclusions. PATIENTS: A total of 250 patients, diagnosed from 1990 to 2024, underwent CYP11B1 sequencing. Forty-four patients carried a novel deep intronic variant (NM_000497.4(CYP11B1):c.954+148C>G). Four were excluded from genotype-phenotype correlation due to missing criteria. MAIN OUTCOME MEASURES: Functional validation was performed using a Minigene Reporter Assay. We retrospectively analyzed genetic findings, clinical features of 11βOHD, and hormonal assays. RESULTS: The Minigene study confirmed that the c.954+148C>G disrupts splicing by activating a cryptic donor-site. Patients carrying this variant had significantly lower steroid precursor levels (p < 0.034) and delayed pubertal onset (p = 0.005) compared to severe variants carriers. CONCLUSIONS: This retrospective study provides genetic data in a wide cohort of 11βOHD, and identifies c.954+148C>G as the most recurrent variant in our Caucasian recruitment. The screen of deep intronic regions, coupled with functional in vitro tools, must not be overlooked in the strategy to avoid diagnostic failure.